NCT00763360View on ClinicalTrials.gov

To Compare the Ability of DiscoVisc® OVD to Protect the Corneal Endothelium and Maintain Anterior Chamber Space With Healon® and Amvisc® PLUS During Cataract Surgery.

PHASE4CompletedINTERVENTIONAL
Enrollment

184

Participants

Timeline

Start Date

May 31, 2008

Primary Completion Date

September 30, 2010

Conditions
Cataract
Interventions
DEVICE

DisCoVisc®

Injection of DisCoVisc® Ophthalmic Viscosurgical Device (OVD) into the anterior chamber prior to and throughout the cataract surgery procedure

DRUG

Healon

Injection of Healon into the anterior chamber prior to and throughout the cataract surgery procedure

DRUG

Amvisc Plus

Injection of Amvisc Plus into the anterior chamber prior to and throughout the cataract surgery procedure

Trial Locations (1)

76134

Alcon Call Center, Fort Worth

Sponsors

Lead Sponsor

Alcon Research
All Listed Sponsors
lead

Alcon Research

INDUSTRY

NCT00763360 - To Compare the Ability of DiscoVisc® OVD to Protect the Corneal Endothelium and Maintain Anterior Chamber Space With Healon® and Amvisc® PLUS During Cataract Surgery. | Biotech Hunter | Biotech Hunter